Current Cardiovascular Risk Reports最新文献

{"title":"Atrial Fibrillation in Women: from Epidemiology to Treatment","authors":"K. Tamirisa, C. Dye, I. Ekeruo, A. Volgman","doi":"10.1007/s12170-022-00707-w","DOIUrl":"https://doi.org/10.1007/s12170-022-00707-w","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"1 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41801256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.","authors":"Sean Paul Gaine, Renato Quispe, Jaideep Patel, Erin D Michos","doi":"10.1007/s12170-022-00694-y","DOIUrl":"10.1007/s12170-022-00694-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>The primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on optimizing cardiovascular health and appropriate pharmacotherapy, a mainstay of which is low-density lipoprotein-cholesterol (LDL-C) lowering. Typically, statin therapy remains the first line approach. Advances in technology and understanding of lipid metabolism have facilitated the development of several novel therapeutic targets and medications within the last decade. This review focuses on medications recently approved by the U.S. Food and Drug Administration (FDA) for the reduction of LDL-C and ASCVD risk, as well as new therapies in the pipeline.</p><p><strong>Recent findings: </strong>Novel lipid therapies aim to lower risk of ASCVD by targeting reduction of atherogenic compounds, such as LDL, lipoprotein(a) (Lp(a)), and triglyceride-rich lipoproteins. Evolocumab and alirocumab, monoclonal antibody proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors which lower LDL-C by approximately 60%, have emerged as important therapies for use in patients with ASCVD as well as familial hypercholesterolemia (FH). Bempedoic acid, an ATP citrate lyase inhibitor, is an oral medication recently approved that can lower LDL-C by approximately 18% alone and 38% when combined with ezetimibe. Inclisiran, a small-interfering RNA (siRNA) molecule which inhibits the translation of PCSK9, is the most recently FDA-approved LDL-C lowering medication, and can reduce LDL-C by approximately 50% with twice yearly subcutaneous dosing. The cardiovascular outcome trials for bempedoic acid and inclisiran are still on-going. Evinacumab, a monoclonal antibody which targets angiopoietin-like protein 3 (ANGPTL3), has been approved for use in patients with homozygous FH. SiRNAs and anti-sense oligonucleotides (ASO) facilitating selective inhibition of the production of targeted proteins including Lp(a) and ANGLPTL3 are active areas of clinical investigation.</p><p><strong>Summary: </strong>Recently several novel LDL-C lowering medications have been approved. New therapeutic targets have been identified and present additional means of lowering LDL-C and other atherogenic compounds for patients who remain at high ASCVD risk.</p>","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 9","pages":"69-78"},"PeriodicalIF":2.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543364/pdf/nihms-1819176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10133436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary Artery Calcium-Based Approach to Lipid Management","authors":"Ayeeshik Kole, P. Joshi","doi":"10.1007/s12170-022-00704-z","DOIUrl":"https://doi.org/10.1007/s12170-022-00704-z","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"1 1","pages":"1 - 14"},"PeriodicalIF":1.9,"publicationDate":"2022-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47924432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk","authors":"V. Bharadiya, Swasti Rawal, V. Jain, P. Chevli, Anurag Mehta","doi":"10.1007/s12170-022-00702-1","DOIUrl":"https://doi.org/10.1007/s12170-022-00702-1","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 1","pages":"131 - 144"},"PeriodicalIF":1.9,"publicationDate":"2022-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45421694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Health of Black Women Before, During, and After Pregnancy: A Call to Action and Implications for Prevention","authors":"R. Bond, Kameelah Phillips, Kendra N. Ivy, Vanessa Ogueri, B. Parapid, S. C. Miller, Annette K. Ansong","doi":"10.1007/s12170-022-00703-0","DOIUrl":"https://doi.org/10.1007/s12170-022-00703-0","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 1","pages":"171-180"},"PeriodicalIF":1.9,"publicationDate":"2022-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43019176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and Ethnic Disparities in Cardiovascular Disease Risk Among Patients with Chronic Kidney Disease","authors":"D. Adedinsewo, Ivan E. Porter, R. White, L. Hickson","doi":"10.1007/s12170-022-00701-2","DOIUrl":"https://doi.org/10.1007/s12170-022-00701-2","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 1","pages":"145 - 157"},"PeriodicalIF":1.9,"publicationDate":"2022-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44491779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Differences in Cardiomyopathy","authors":"Chris Taylor, Emily S. Lau","doi":"10.1007/s12170-022-00700-3","DOIUrl":"https://doi.org/10.1007/s12170-022-00700-3","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 1","pages":"159 - 170"},"PeriodicalIF":1.9,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45314500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Atrial Fibrillation Symptoms to Guide Treatment: Becoming PROs at Improving Quality of Life","authors":"B. Zenger, B. Steinberg","doi":"10.1007/s12170-022-00695-x","DOIUrl":"https://doi.org/10.1007/s12170-022-00695-x","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 1","pages":"79 - 86"},"PeriodicalIF":1.9,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45274981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arrhythmia-Induced Cardiomyopathy: Mechanisms and Risk Assessment to Guide Management and Follow-Up","authors":"Luke Chong, R. Gopinathannair, Ali Ahmad, Philip L. Mar, B. Olshansky","doi":"10.1007/s12170-022-00699-7","DOIUrl":"https://doi.org/10.1007/s12170-022-00699-7","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 1","pages":"121 - 129"},"PeriodicalIF":1.9,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43446601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a)—When to Screen and How to Treat","authors":"N. Patel, N. Mittal, P. Choubdar, P. Taub","doi":"10.1007/s12170-022-00698-8","DOIUrl":"https://doi.org/10.1007/s12170-022-00698-8","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":"16 1","pages":"111-120"},"PeriodicalIF":1.9,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44537346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}